Abstract 804
Background
A decrease lymphocyte to monocyte ratio (LMR) has been reported to be related with worsen prognosis for certain hematologic and solid malignancies. Also pretreatment LMR is associated with the prognosis of patients with breast cancer. However, relationship between treatment-related low LMR and prognostic impact has not well been investigated in breast cancer. The purpose of this study is to evaluate the relationship between radiotherapy (RT)-induced low LMR and recurrence in patients with breast cancer.
Methods
We retrospectively reviewed 1,735 patients with stage I to III breast cancer treated with breast conserving surgery (BCS) and adjuvant RT at Gangnam Severance Hospital and Severance Hospital from January 2006 to 2016 December. The values of LMR were calculated at baseline (A1), before the first RT administration (A2) and before the last RT administration (A3). The reference point of RT-induced low LMR was defined as ≤ 2.6 used in other studies. The recurrence-free survival (RFS) was compared according to RT-induced LMR.
Results
We retrospectively reviewed 1,735 patients with stage I to III breast cancer treated with breast conserving surgery (BCS) and adjuvant RT at Gangnam Severance Hospital and Severance Hospital from January 2006 to 2016 December. The values of LMR were calculated at baseline (A1), before the first RT administration (A2) and before the last RT administration (A3). The reference point of RT-induced low LMR was defined as ≤ 2.6 used in other studies. The recurrence-free survival (RFS) was compared according to RT-induced LMR.
Conclusions
We demonstrated that RT-induced low LMR is a poor prognostic factor for patients with BCS and adjuvant RT.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3191 - The efficacy and safety of lenvatinib in patients who did not meet the inclusion criteria of the phase 3 trial (REFLECT trial) and those with BCLC Stage B hepatocellular carcinoma - A nationwide multicenter study in Japan-
Presenter: Azusa Sakamoto
Session: Poster Display session 2
Resources:
Abstract
1529 - Prognostic and predictive value of baseline alpha-fetoprotein (AFP) in patients with advanced hepatocellular carcinoma (HCC) treated with ramucirumab from two phase 3 studies (REACH, REACH-2)
Presenter: Andrew Zhu
Session: Poster Display session 2
Resources:
Abstract
2767 - Effect of second-line cabozantinib on health states for patients with advanced hepatocellular carcinoma (aHCC) after sorafenib: QTWiST analysis from the CELESTIAL study
Presenter: Nicholas Freemantle
Session: Poster Display session 2
Resources:
Abstract
2150 - Alpha-fetoprotein (AFP) response in patients with unresectable hepatocellular carcinoma (HCC) in the phase 3 RESORCE trial
Presenter: Jordi Bruix
Session: Poster Display session 2
Resources:
Abstract
3437 - Phase I/II trial of NBTXR3 activated by SBRT in patients with hepatocellular carcinoma or liver metastasis
Presenter: Marc Pracht
Session: Poster Display session 2
Resources:
Abstract
1758 - Efficacy and safety of ramucirumab (RAM) for advanced hepatocellular carcinoma (HCC) with elevated alpha-fetoprotein (AFP) following first-line sorafenib across age subgroups in two global phase 3 trials (REACH and REACH-2)
Presenter: Masatoshi Kudo
Session: Poster Display session 2
Resources:
Abstract
1192 - Ramucirumab in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha fetoprotein (AFP): An exposure–response analysis
Presenter: Josep Llovet
Session: Poster Display session 2
Resources:
Abstract
1600 - Outcomes of Hepatocellular Carcinoma (HCC) Patients Treated with Nivolumab: The Mount Sinai Hospital Experience.
Presenter: Sirish Dharmapuri
Session: Poster Display session 2
Resources:
Abstract
2364 - Pembrolizumab vs Chemotherapy in Patients With Advanced/Metastatic Adenocarcinoma (AC) or Squamous Cell Carcinoma (SCC) of the Esophagus as Second-Line Therapy: Analysis of the Chinese Subgroup in KEYNOTE-181
Presenter: Jia Chen
Session: Poster Display session 2
Resources:
Abstract
1933 - A national comparative effectiveness study to assess definitive chemoradiation regimens in proximal oesophageal squamous cell cancer
Presenter: Judith de Vos-Geelen
Session: Poster Display session 2
Resources:
Abstract